Holen Sie sich die Stockscreener-App
9.8224
0.72%
0.0524
Schlusskurs vom Vortag:
$9.77
Offen:
$9.24
24-Stunden-Volumen:
1.60M
Relative Volume:
0.85
Marktkapitalisierung:
$854.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-4.5265
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
-6.37%
1M Leistung:
+2.82%
6M Leistung:
+52.09%
1J Leistung:
-44.75%
1-Tages-Spanne:
$8.825
$10.10
1-Wochen-Bereich:
$8.825
$10.73
52-Wochen-Spanne:
$5.41
$19.73
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
9.845 | 848.01M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.76 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.65 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
426.83 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
843.03 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.67 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Guggenheim | Neutral |
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Earnings call transcript: Kura Oncology Q3 2025 reports wider EPS loss - Investing.com
Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Kura Oncology to present ziftomenib combination data at ASH meeting By Investing.com - Investing.com Australia
KURA Reports Lower Q3 Revenue, Focuses on Expanding Oncology Pip - GuruFocus
Kura Oncology: Q3 Earnings Snapshot - San Francisco Chronicle
Kura Oncology Eyes FDA Decision As Losses Mount And Optimism Grows - Finimize
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q3 Revenue $20.8M, vs. FactSet Est of $18.9M - MarketScreener
Kura Oncology (KURA) Reports Q3 Earnings Miss - GuruFocus
Kura Oncology Inc Reports Q3 2025 Earnings: EPS Matches Estimates at -$0.85, Revenue Falls Short at $20.8 Million - GuruFocus
KURA ONCOLOGY Earnings Results: $KURA Reports Quarterly Earnings - Quiver Quantitative
Kura Oncology Q3 net loss widens to $74.1 mln - TradingView
Kura Oncology Highlights Progress with Ziftomenib for AML as FDA Review Continues and Phase 3 Trials Accelerate - Quiver Quantitative
BRIEF-Kura Oncology Q3 Collaboration Revenue USD 20.75 Million - TradingView
Kura Oncology Reports Third Quarter 2025 Financial Results - Bakersfield.com
Is Kura Oncology Inc. stock recession proofIPO Watch & Trade Opportunity Analysis - newser.com
AlphaQuest LLC Sells 29,555 Shares of Kura Oncology, Inc. $KURA - MarketBeat
How to monitor Kura Oncology Inc. with trend dashboardsMarket Performance Report & Verified Short-Term Plans - newser.com
Kura Oncology (KURA) Secures $30 Million Milestone Payment - GuruFocus
Kura Oncology receives second $30 million milestone payment from Kyowa Kirin - Investing.com
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program with Kyowa Kirin - MarketScreener
Candlestick signals on Kura Oncology Inc. stock todayPortfolio Update Report & Breakout Confirmation Trade Signals - newser.com
Kura Oncology to present ziftomenib combination data at ASH meeting - Investing.com
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting - 富途牛牛
Why Kura Oncology Inc. stock attracts high net worth investorsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings - GuruFocus
Signal strength of Kura Oncology Inc. stock in tech scannersJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Is Kura Oncology (NASDAQ:KURA) Weighed On By Its Debt Load? - simplywall.st
How Kura Oncology Inc. stock reacts to Fed rate cutsPortfolio Profit Report & Expert Verified Movement Alerts - newser.com
Applying sector rotation models to Kura Oncology Inc.Weekly Trading Summary & High Accuracy Trade Alerts - newser.com
What momentum indicators show for Kura Oncology Inc. stockMarket Growth Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Can technical indicators confirm Kura Oncology Inc.’s reversalMarket Activity Summary & Weekly High Return Stock Forecasts - newser.com
Understanding Kura Oncology Inc.’s price movement2025 Market WrapUp & Daily Profit Maximizing Trade Tips - newser.com
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
What drives Kura Oncology Inc stock priceGap Up/Gap Down Analysis & Tap Into the Fastest-Growing Companies - earlytimes.in
Is Kura Oncology Inc. showing signs of accumulationJuly 2025 Decliners & High Conviction Buy Zone Picks - newser.com
Kura Oncology Inc. stock momentum explained2025 AllTime Highs & Reliable Trade Execution Plans - newser.com
What analysts say about Kura Oncology Inc stockGap Up/Gap Down Analysis & Follow Top Performers in the Community - earlytimes.in
Can Kura Oncology Inc. stock resist market sell offs2025 Retail Activity & Weekly High Return Stock Opportunities - newser.com
Kura Oncology (KURA) to Release Earnings on Thursday - MarketBeat
Can Kura Oncology Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Capital Efficiency Focused Strategies - newser.com
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.53%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):